Business Wire

AgroAmerica Presents Its 2022 Sustainability Report: A Future Built to Last

18.7.2023 17:12:00 EEST | Business Wire | Press release

Share

AgroAmerica presented its ninth Sustainability Report. This report provides an updated overview of the performance of the company’s banana division and the achievements made in 2022 through its Corporate Sustainability Strategy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230717281841/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

AgroAmerica's sustainability report details the structure, governance, strategy, and management of the company, with a specific focus on the material issues identified. Over the past year, AgroAmerica has worked on environmental, social, and governance topics that are relevant to the business. (Photo: Business Wire)

"We are pleased to announce that the year 2022 marks the final chapter of our current strategy, as well as the starting point of a significant transformation. In this process, our strong foundation in sustainability will drive a new robust integrated strategy that will shape our path in 2023-24. This exciting step will lead us to continuous improvement and a more sustainable future," explained Fernando Bolaños, CEO of AgroAmerica.

Using a regenerative approach, the company undertakes actions aimed at promoting soil health, resource conservation, biodiversity preservation, and the reduction of carbon emissions. As part of this strategy, AgroAmerica has initiated a project, unique in the region, that protects bees and other pollinators in forest conservation areas located in our operations.

Some of the highlighted achievements included in this report:

  • The installation of a macro sanctuary to house and protect more than 30,000 native bees and pollinators.
  • Receiving the "2022 Conservation Leadership Award" from the RSPO Excellence Awards to the Mayan Biosphere conservation project.
  • Receiving the "Grand Prize in Business Sustainability" from the American Chamber of Commerce for our "Mangrove Ecosystem Restoration Project" on the Pacific Coast of Guatemala.
  • Obtaining the “RSPO certification” in our operations in Panama, meaning that all the operations of the tropical oil division in AgroAmerica are now certified.
  • The generation of over 12,000 direct and indirect jobs that promote gender equality and development opportunities for our employees, their families and our neighboring communities.
  • Contributing to 11 of the United Nations’ Sustainable Development Goals.
  • Holding 11 international certifications related to good practices, sustainable operations, and food quality and safety.
  • The conservation of more than 970 hectares of forests in areas within our company’s operations.

"We are a world-class corporation that adapts to global market challenges to exceed environmental, governance and social expectations and offer high-value-added products to the world," stated Javier Aguirre, Corporate Director.

This report shows our path forward with a renewed focus on sustainability, and reaffirms our company's commitment to the environment, society, and governance in the production of high-quality sustainable food.

See full report here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Susana Perez
Communications and Public Relations Coordinator
sperez@agroamerica.com
(+502) 5554-8774

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye